YAP1 and cholangiocarcinoma: Unlike Golino et al.'s study 34 on cholangiocarcinoma, this work integrates VP's immunomodulatory effects with the specific post-iRFA microenvironment, providing a clearer understanding of how it suppresses residual tumor progression via the YAP-MDSCs axis.